Table 5 Patient distribution (n) between proposed IASLC/ITMIG stages and WHO classification
From: Evaluation of the new TNM-staging system for thymic malignancies: impact on indication and survival
IASLC/ITMIG stages | Total | |||||||
|---|---|---|---|---|---|---|---|---|
I | II | IIIa | IIIb | IVa | IVb | |||
WHO | A | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
AB | 4 | 0 | 0 | 0 | 1 | 0 | 5 | |
B1 | 2 | 0 | 1 | 0 | 2 | 0 | 5 | |
B2 | 9 | 1 | 6 | 0 | 10 | 2 | 28 | |
Mixed B2/B3 | 1 | 0 | 3 | 0 | 4 | 0 | 8 | |
B3 | 4 | 0 | 3 | 2 | 9 | 0 | 18 | |
C | 1 | 0 | 2 | 0 | 4 | 3 | 10 | |
Total | 23 | 1 | 15 | 2 | 30 | 5 | 76 | |